Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.

Saved in:
Bibliographic Details
Title: Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.
Authors: Gamerith, Gabriele1 gabriele.gamerith@i-med.ac.at, Auer, Thomas2, Amann, Arno1, Putzer, Daniel2, Schenk, Bettina3, Kircher, Brigitte1, Hilbe, Wolfgang1, Zwierzina, Heinz1, Loeffler-Ragg, Judith4
Source: Cancer Biology & Therapy. Mar2014, Vol. 15 Issue 3, p266-270. 5p.
Database: Academic Search Ultimate
Description
ISSN:15384047
DOI:10.4161/cbt.27327